Search

Displaying results 4311 - 4320 of 10000 in total
  1. Drug

    R343

    go.drugbank.com/drugs/DB06316
    Investigational

    R343, was investigated in clinical trial NCT01591044 to evaluate its safety and efficacy in patients with mild to moderate asthma.

    Synonyms: 2- {3- [4-(2,2-Difluoro-3 -oxo-3,4-dihydro-2H-benzo [1,4] oxazin-6-ylamino)5-fluoro-pyrimidin-2-ylamino]phenoxy}N-methyl-acetamide
  2. Drug

    Flutemetamol

    go.drugbank.com/drugs/DB15058
    Investigational

    Flutemetamol is under investigation in clinical trial NCT02353949 (Investigating the Clinical Consequences of Flutemetamol-PET-scanning).

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Beinaglutide

    go.drugbank.com/drugs/DB15072
    Investigational

    Beinaglutide is under investigation in clinical trial NCT03829891 (Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus).

    Categories: Drugs Used in Diabetes
  4. Drug

    Methoxyamine

    go.drugbank.com/drugs/DB06328
    Investigational

  5. Drug

    Deserpidine

    go.drugbank.com/drugs/DB01089
    ApprovedWithdrawn

    Deserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure

  6. Drug

    Diaziquone

    go.drugbank.com/drugs/DB17174
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Phosphocysteamine

    go.drugbank.com/drugs/DB17640
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Sufugolix

    go.drugbank.com/drugs/DB06494
    Experimental

  9. Drug

    Emicizumab

    go.drugbank.com/drugs/DB13923
    ApprovedInvestigational

    Emicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X. … Emicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co.

  10. Drug

    LY-517717

    go.drugbank.com/drugs/DB05713
    Investigational

    LY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).